ALX Oncology Files Q1 2025 10-Q
Ticker: ALXO · Form: 10-Q · Filed: May 8, 2025 · CIK: 1810182
Sentiment: neutral
Topics: 10-Q, pharmaceutical, clinical-stage, collaboration
Related Tickers: ALXO
TL;DR
**ALXO Q1 2025 10-Q FILED. Financials and ops details inside.**
AI Summary
ALX Oncology Holdings Inc. reported its first quarter 2025 results on May 8, 2025. The company's financial statements for the period ending March 31, 2025, are detailed in this 10-Q filing. Key financial data and operational updates are provided, though specific dollar amounts for revenue, expenses, or cash flow are not immediately apparent in this header information.
Why It Matters
This filing provides crucial financial and operational updates for ALX Oncology Holdings Inc., offering insights into the company's performance and strategic direction for investors and stakeholders.
Risk Assessment
Risk Level: medium — As a pharmaceutical company in clinical development, ALX Oncology faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Period End Date (Quarterly financial reporting period)
- 20250508 — Filing Date (Date the 10-Q was submitted to the SEC)
Key Players & Entities
- ALX ONCOLOGY HOLDINGS INC (company) — Filer
- 20250331 (date) — Period of Report
- 20250508 (date) — Filing Date
- 001-39386 (company) — SEC File Number
- Tallac Therapeutics (company) — Collaboration Agreement
- ScalmiBio Inc (company) — Collaboration Agreement
- Oxford Finance And Silicon Valley Bank Loan Agreement (company) — Loan Agreement
FAQ
What is the primary business of ALX Oncology Holdings Inc.?
ALX Oncology Holdings Inc. is involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].
When is the period of report for this 10-Q filing?
The period of report for this 10-Q filing is March 31, 2025.
What is the filing date of this 10-Q?
This 10-Q filing was submitted on May 8, 2025.
Are there any mentioned collaboration agreements?
Yes, the filing mentions collaboration agreements with Tallac Therapeutics and ScalmiBio Inc.
What loan agreement is referenced in the filing?
The filing references the Oxford Finance And Silicon Valley Bank Loan Agreement, specifically mentioning Tranche B.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding ALX ONCOLOGY HOLDINGS INC (ALXO).